Compare TG Therapeutics Inc (TGTX) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs TeraWulf Inc — how do they compare? TG Therapeutics Inc trades at $54.83 (market cap $8.16B), while TeraWulf Inc trades at $13.83 (market cap $6.81B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and TeraWulf Inc for 17 Days on average.
| TGTX | WULF | |
|---|---|---|
Market Cap | $8.16B | $6.81B |
Volume | 1,735,121 | 45,841,998 |
Sector | Health | Financials |
52-Week High | $59.06 | $28.98 |
52-Week Low | $26.94 | $10.99 |
Typical Hold Time | 16 Days | 17 Days |
Enterprise Value | $8.37B | $9.43B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
TeraWulf (WULF) trades at $13.73, down 4.65% today, amid a challenging fundamental backdrop with significant losses and negative margins. The stock shows technical bearish signals with moving averages indicating selling pressure, though oversold RSI levels suggest potential for near-term bounce. Recent news highlights the company's pivot to AI data center operations, with positive analyst coverage despite poor financial performance.
While analyst consensus remains strongly bullish with a $34.92 price target, fundamental weaknesses including negative net income margin of -1,179.94% and high valuation ratios present substantial risks. The company's transition to AI hosting offers growth potential but requires careful monitoring of cash flow sustainability and competitive positioning in the evolving data center market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
